A former failure in PhII, the go-go FDA says it’s ready to consider an accelerated shortcut for Ultragenyx’s UX007

More than a year after Ultragenyx $RARE announced the failure of a Phase II study for its seizure medication UX007, the rare disease specialist says the FDA has now offered a thumbs-up for its willingness to consider an accelerated approval for a different indication.